SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (647)4/26/2004 11:54:55 AM
From: tuck  Read Replies (1) of 897
 
FBR's target came in range this morning as Tarceva results lifted any stock with an oncology program. This is understandable for IMCL, and ABGX, even for REGN, all of which have drug a that target the EGF receptor in some way. But ONXX' drug is a raf kinase inhibitor and a small molecule. Antiangiogenesis is involved, but the similarities end there. BSCP figures the hype will start dying a little in a day or so and shorts a half position of ONXX at $54.65 (manager has done similar move in real life) for a quick few bucks.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News